Granted Patent
B2
US 9,764,001 · App. 14/948,539 · Granted Sep 19, 2017
Target for diagnosis and treatment of diabetes and cardiovascular diseases
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Diagnostic, prognostic, and treatment methods, compositions, and kits for enhancing insulin secretion and beta cell numbers and functions, and controlling glycemia associated with diabetes, obesity, atherosclerosis, stroke, myocardial infarction, and other cardiovascular diseases, by modulating FKN/CX3CR1 expression levels or activities, and its downstream signaling pathways in a subject in need or at risk.
Claims (1)
1. A method for increasing insulin secretion comprising administering to a subject in need thereof an effective amount of a composition comprising an agent that activates fractalkine/CX3C chemokine receptor 1 , wherein said agent comprises soluble fractalkine.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Jul 11, 2016
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039299/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 23, 2015
From: OLEFSKY, JERROLD M.; LEE, YUN SOK
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 037115/0712 →
Continuity (4)
Continuation
PCTUS2013027860
· Feb 27, 2013
Provisional Application
61605444
· Mar 1, 2012